Company / Shareholders' Equity
BeOne Medicines Ltd. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$4.4B
FY2025
5-year range
$3.3B / $6.1B
FY2021-FY2025
Trend
+30.9%
vs FY2024
Sector context
#20 of 213
Health Care
What the data says
Among 213 Health Care companies, BeOne Medicines Ltd. is in the top 9% for shareholders' equity. Shareholders' Equity returned to growth in FY2025 after 3 years of decline, reaching $4.4B.
Based on SEC 10-K filings.
$4.4B in FY2025 with a 5-year CAGR of +2.4%. Top quartile in the Health Care sector.
Improved from $3.5B to $4.4B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -0.2%
- 5-Year CAGR
- +2.4%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 213This company $4.4B Sector average $2.5B
▼
+71.1% above sector average
Key checks
Key Insights
- 5-year CAGR of +2.4%, indicating consistent growth.
- In FY2025, shareholders' equity increased 30.9% year-over-year.
- Ranks #20 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.4B | +30.9% |
| FY2024 | $3.3B | -5.8% |
| FY2023 | $3.5B | -19.3% |
| FY2022 | $4.4B | -28.5% |
| FY2021 | $6.1B | +58.5% |
| FY2020 | $3.9B | +302.1% |
| FY2019 | $962.2M | -44.7% |
| FY2018 | $1.7B | +159.7% |
| FY2017 | $669.8M | +89.8% |
| FY2016 | $352.9M | +446.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026